Anastrozole Plus Lonafarnib (SCH 66336) or Plus Placebo for the Treatment of Advanced Breast Cancer (P03480)
Status:
Completed
Trial end date:
2009-05-01
Target enrollment:
Participant gender:
Summary
Primary Objective(s):
- To compare the activity (progression-free survival [PFS]) of anastrozole in combination
with lonafarnib to that of anastrozole in combination with placebo in subjects with
hormone-sensitive ADVANCED breast cancer.
Secondary Objective(s):
- To determine the effects of anastrozole in combination with lonafarnib on objective
response, duration of response, overall survival, and safety in subjects with advanced
breast cancer. To assess the exposure and pharmacokinetics of lonafarnib and anastrozole
in the subject population.